STT COMP PTX TA LONG
Size
| 1 | | Market Capitalisation | 5,511,322 |
|---|
| 2 | ASX Rank | 941 of 2,282 |
|---|
| 3 | Sector Rank | 75 of 177 |
|---|
Key Information
| Shares Issued | 641,729,568 |
|---|
| 1 | Sector | Healthcare |
|---|
| 2 | Similar Companies | OIL / MDR / ANP |
|---|
| 3 | EPS | -$0.007 |
|---|
| 4 | DPS | $0.00 |
|---|
| 5 | NTA per share | $0.03 |
|---|
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers.
Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches which seek to improve patient outcomes, whilst also new tools for clinicians in combating cancer.
Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers.
Prescient has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.
Prescient Therapeutics is working to rapidly expand the application of universal CAR-T therapies, capable of addressing all cancers, including solid tumours.
OmniCAR, a universal CAR-T platform employing technology licensed from UPenn, the pioneer and world leader in CAR-T, as well as Oxford University, will allow unprecedented control and flexibility over current generation CAR-T approaches. It combines the cancer-killing capabilities of a T-cell with the control and pharmacology of a drug.
Today's Announcement"Prescient Therapeutics Limited is a the clinical stage oncology company developing personalised medicine approaches to cancer, including targeted therapies, cell therapy enhancements and next generation CAR-T therapies.
Today they announced results from the PTX-100 Phase 1b basket trial in solid and hematological cancers.
PTX-100 exhibited an excellent safety profile and demonstrated biological activity in two highly pre-treated T cell lymphoma (TCL) patients with aggressive disease.
Prescient will now advance PTX-100 to an expansion cohort study focusing on TCL, which represents an area of significant unmet clinical need."
I believe that the market may have overreacted to the news and offer this as a short term long prospect by providing 2 charts to support my belief that it may move forward.
Daily chart.Please observe a similar pull back in January as indicated by the red down arrow (also after an announcement) and also the RSI support level
https://www.tradingview.com/x/iwwYl4kT/
Weekly Chart
Likewise the longer time frame similarly supports my theory that this may correct and move forward. (same as indicated by the red down arrow and also the RSI support level) https://www.tradingview.com/x/sM8rBxxq/
